Shire Pharmaceuticals Limited

Hampshire International Business Park, Chineham, Basingstoke, Hampshire , RG24 8EP
Telephone: +44 (0)1256 894 000
WWW: http://www.shire.com
Medical Information Direct Line: 0800 055 6614
Medical Information e-mail: medinfoglobal@shire.com
Customer Care direct line: +44 (0)1256 894 107
Summary of Product Characteristics last updated on the eMC: 29/09/2009
SPC Calcichew D3 Chewable Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 29/09/2009 and displayed until Current
Reasons for adding or updating:
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   26-Apr-2007
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

None provided
Updated on 27/06/2007 and displayed until 29/09/2009
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 4 - Special Precautions for Storage
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   04/2007
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Changes to add 'May be chewed or sucked" to posology, naming of excipients and removal of 'to protect from moisture'; addition of soybean oil warning in contraindications; update to warnings.
Updated on 16/03/2007 and displayed until 27/06/2007
Reasons for adding or updating:
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   02/2007
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Update Section 4.9 Overdosage in line with MHRA guidelines on gastric lavage

Updated on 15/03/2007 and displayed until 16/03/2007
Reasons for adding or updating:
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   02/2007
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Update to Section 4.9 Overdose in line with MHRA guidelines on Gastric Lavage

Updated on 27/05/2004 and displayed until 15/03/2007
Reasons for adding or updating:
  • Change to section 1 - trade name
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 3 - pharmaceutical form
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 6. 6 - Instruction for Use/Handling
  • Change to section 10 (date of (partial) revision of the text
Updated on 10/02/2003 and displayed until 27/05/2004
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
Updated on 07/02/2003 and displayed until 10/02/2003
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
Updated on 23/10/2001 and displayed until 07/02/2003
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 12/07/2001 and displayed until 23/10/2001
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
Updated on 06/09/1999 and displayed until 12/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   calcium carbonate
   colecalciferol (vitamin d3)


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk